Zivo Bioscience, Inc. (ZIVO) stock
ZIVOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.80+0.30 (+4.62%)
Close on Oct 19, 2026Market cap $25.96MP/E –Yield –
Zivo Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
Zivo Bioscience's R&D Expenses for the twelve months ending Sep 30, 2025 was $3.70M, up 15.4% year over year. For fiscal 2024 it was $3.13M, up 127.7% from the year before. Over ten years it grew 4.7% a year on average. The highest annual figure on record is $3.75M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.13M | +127.7% |
| FY2023 | Dec 31, 2023 | $1.38M | -38.5% |
| FY2022 | Dec 31, 2022 | $2.24M | +14.9% |
| FY2021 | Dec 31, 2021 | $1.95M | -48.1% |
| FY2020 | Dec 31, 2020 | $3.75M | +62.8% |
| FY2019 | Dec 31, 2019 | $2.31M | -18.0% |
| FY2018 | Dec 31, 2018 | $2.81M | +18.2% |
| FY2017 | Dec 31, 2017 | $2.38M | +201.8% |
| FY2016 | Dec 31, 2016 | $788.97K | -23.6% |
| FY2015 | Dec 31, 2015 | $1.03M | -47.6% |
| FY2014 | Dec 31, 2014 | $1.97M | +93.6% |
| FY2013 | Dec 31, 2013 | $1.02M | +50.3% |
| FY2012 | Dec 31, 2012 | $677.49K | +79.3% |
| FY2011 | Dec 31, 2011 | $377.89K | -4.5% |
| FY2010 | Dec 31, 2010 | $395.57K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | $203.44K | -37.7% |
| Q2 FY2025 | Jun 30, 2025 | $479.66K | -78.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.77M | +785.4% |
| Q4 FY2024 | Dec 31, 2024 | $243.48K | -22.1% |
| Q3 FY2024 | Sep 30, 2024 | $326.36K | +47.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.25M | +409.4% |
| Q1 FY2024 | Mar 31, 2024 | $312.77K | -22.2% |
| Q4 FY2023 | Dec 31, 2023 | $312.47K | -39.8% |
| Q3 FY2023 | Sep 30, 2023 | $220.65K | -63.4% |
| Q2 FY2023 | Jun 30, 2023 | $442.11K | +0.9% |
| Q1 FY2023 | Mar 31, 2023 | $401.80K | -40.9% |
| Q4 FY2022 | Dec 31, 2022 | $519.35K | -3.8% |
| Q3 FY2022 | Sep 30, 2022 | $603.11K | +47.5% |
| Q2 FY2022 | Jun 30, 2022 | $438.05K | -6.4% |
| Q1 FY2022 | Mar 31, 2022 | $679.77K | +5.1% |
| Q4 FY2021 | Dec 31, 2021 | $539.92K | +20.7% |
| Q3 FY2021 | Sep 30, 2021 | $409.01K | -68.4% |
| Q2 FY2021 | Jun 30, 2021 | $467.92K | +7.1% |
| Q1 FY2021 | Mar 31, 2021 | $646.75K | -59.0% |
| Q4 FY2020 | Dec 31, 2020 | $447.20K | -4.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.29M | +146.4% |
| Q2 FY2020 | Jun 30, 2020 | $436.70K | -53.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.58M | +330.6% |
| Q4 FY2019 | Dec 31, 2019 | $467.49K | -16.3% |
| Q3 FY2019 | Sep 30, 2019 | $525.58K | -5.3% |
| Q2 FY2019 | Jun 30, 2019 | $947.91K | +22.5% |
| Q1 FY2019 | Mar 31, 2019 | $366.06K | -60.5% |
| Q4 FY2018 | Dec 31, 2018 | $558.70K | -45.6% |
| Q3 FY2018 | Sep 30, 2018 | $555.19K | +0.8% |
| Q2 FY2018 | Jun 30, 2018 | $773.99K | +56.2% |
| Q1 FY2018 | Mar 31, 2018 | $927.12K | +200.0% |
| Q4 FY2017 | Dec 31, 2017 | $1.03M | +445.8% |
| Q3 FY2017 | Sep 30, 2017 | $550.55K | +338.0% |
| Q2 FY2017 | Jun 30, 2017 | $495.52K | +204.5% |
| Q1 FY2017 | Mar 31, 2017 | $309.02K | -1.1% |
| Q4 FY2016 | Dec 31, 2016 | $188.01K | -27.1% |
| Q3 FY2016 | Sep 30, 2016 | $125.70K | – |
| Q2 FY2016 | Jun 30, 2016 | $162.71K | – |
| Q1 FY2016 | Mar 31, 2016 | $312.56K | – |
| Q4 FY2015 | Dec 31, 2015 | $257.84K | – |
See a number that looks wrong?